Unity Biotechnology

American biotechnology company in the San Francisco bay area, founded in 2011 and listed on the American market in 2018, which works on medicines for diseases of ageing. Built its research on senolytics, compounds that clear senescent cells, and has run clinical programmes in eye disease including a therapy for diabetic macular oedema and age related macular degeneration, alongside earlier work in osteoarthritis.